Tissue persistence and prevalence of B19 virus types 1-3

Future Virology

Volumn 2, Issue 4, 2007, Pages 377-388

  Hokynar, Kati ^a   Norja, Päivi ^a   Hedman, Klaus ^a   Söderlund Venermo, Maria ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

Author keywords

B19; DNA persistence; Epidemiology; Genotype; Human parvovirus; Prevalence

Indexed keywords

MESSENGER RNA; SINGLE STRANDED DNA; VIRUS DNA; VIRUS PROTEIN; VIRUS RNA;

ANEMIA; ARTHROPATHY; CELL TYPE; DIAGNOSTIC VALUE; DNA VIRUS; ERYTHEMA INFECTIOSUM; FETUS DEATH; GENETIC VARIABILITY; HOST CELL; HUMAN; IMMUNOCOMPETENCE; MOLECULAR DYNAMICS; MUTATIONAL ANALYSIS; NONHUMAN; PARVOVIRUS; PERSISTENT VIRUS INFECTION; PREVALENCE; PRIORITY JOURNAL; PROTEIN SYNTHESIS; REVIEW; RNA SYNTHESIS; STRAIN DIFFERENCE; SYMPTOMATOLOGY;

PARVOVIRUS; SSDNA VIRUSES;

EID: 34447300947     PISSN: 17460794     EISSN: None     Source Type: Journal    
DOI: 10.2217/17460794.2.4.377     Document Type: Review

References (137)

1. Cossart YE, Field AM, Cant B, Widdows D: Parvovirus-like particles in human sera. Lancet 1, 72-73 (1975).
2. Doerig C, Beard P, Hirt B: A transcriptional promoter of the human parvovirus B19 active in vitro and in vivo. Virology 157, 539-542 (1987).
3. Ozawa K, Ayub J, Hao YS, Kurtzman G, Shimada T, Young N: Novel transcription map for the B19 (human) pathogenic parvovirus. J. Virol. 61, 2395-2406 (1987).
4. Zhi N, Mills IP, Lu J, Wong S, Filippone C, Brown KE: Molecular and functional analyses of a human parvovirus. B19 infectious clone demonstrates essential roles for NS1, VP1, and the 11-kilodalton protein in virus replication and infectivity. J. Virol. 80, 5941-5950 (2006).
5. Anderson LJ, Isou C, Parker RA et al.: Detection of antibodies and antigens of human parvovirus B19 by enzyme-linked immunosorbent assay, J. Clin. Microbiol. 24, 522-526 (1986).
6. Cohen BJ, Buckley MM: The prevalence of antibody to human parvovirus B19 in England and Wales. J. Med. Microbiol. 25, 151-153 (1988).
7. Anderson MJ, Higgins PG, Davis LR et al.: Experimental parvoviral infection in humans. J. Infect. Dis. 152, 257-265 (1985).
8. Mortimer PP, Luban NL, Kelleher JF, Cohen BJ: Transmission of serum parvovirus-like virus by clotting factor concentrates. Lancet 2, 482-484 (1983).
9. Yee TT, Lee CA, Pasi KJ: Life-threatening human parvovirus B19 infection in immunocompetent haemophilia. Lancet 345, 794-795 (1995).
10. Zanella A, Rossi F, Cesana C et al.: Transfusion-transmitted human parvovirus B19 infection in a thalassemic patient. Transfusion 35, 769-772 (1995).
11. Blumel J, Schmidt I, Effenberger W et al.: Parvovirus B19 transmission by heat-treated clotting factor concentrates. Transfusion 42, 1473-1481 (2002).
12. Brown T, Anand A, Ritchie LD, Clewley JP, Reid TM: Intrauterine parvovirus infection associated with hydrops fetalis. Lancet 2, 1033-1034 (1984).
13. Allander T, Tammi MT, Eriksson M, Bjerkner A. Tiveljung-Lindell A, Andersson B: Cloning of a human parvovirus by molecular screening of respiratory tract samples. Proc. Natl. Acad. Sci. USA 102, 12891-12896 (2005).
14. Jones MS, Kapoor A, Lukashov VV, Simmonds P, Hecht F, Delwart E: New DNA viruses identified in patients with acute viral infection syndrome. J. Virol. 79, 8230-8236 (2005).
15. Fryer JF, Kapoor A, Minor PD, Delwart E, Baylis SA: Novel parvovirus and related variant in human plasma. Emerg. Infect. Dis. 12, 151-154 (2006).
16. Kerr JR: Pathogenesis of parvovirus B19 infection: host gene variability, and possible means and effects of virus persistence. J. Vet. Med. B Infect. Dis. Vet. Public Health 52, 335-339 (2005).
17. Anderson MJ, Lewis E, Kidd IM, Hall SM, Cohen BJ: An outbreak of erythema infectiosum associated with human parvovirus infection. J. Hyg. (Lond.) 93, 85-93 (1984).
18. Cohen BJ, Buckley MM, Clewley JP, Jones VE, Puttick AH, Jacoby RK: Human parvovirus infection in early rheumatoid and inflammatory arthritis. Ann. Rheum. Dis. 45, 832-838 (1986).
19. Arnett FC, Edworthy SM, Bloch DA et al.: The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 31, 315-324 (1988).
20. Naides SJ, Scharosch LL, Foto F, Howard EJ: Rheumatologic manifestations of human parvovirus B19 infection in adults. Initial two-year clinical experience. Arthritis Rheum. 33, 1297-1309 (1990).
21. Pattison JR, Jones SE, Hodgson J et al.: Parvovirus infections and hypoplastic crisis in sickle-cell anaemia. Lancet 1, 664-665 (1981).
22. Kurtzman GJ, Ozawa K, Cohen B, Hanson G, Oseas R, Young NS: Chronic bone marrow failure due to persistent B19 parvovirus infection. N. Engl. J. Med. 317, 287-294 (1987).
23. Kurtzman GJ, Cohen B, Meyers P, Amunullah A, Young NS: Persistent B19 parvovirus infection as a cause of severe chronic anaemia in children with acute lymphocytic leukaemia. Lancet 2, 1159-1162 (1988).
24. Kurtzman G, Frickhofen N, Kimball J, Jenkins DW, Nienhuis AW, Young NS: Pure red-cell aplasia of 10 years' duration due to persistent parvovirus B19 infection and its cure with immunoglobulin therapy. N. Engl. J. Med. 321, 519-523 (1989).
25. Kühl U, Pauschinger M, Noutsias M et al.: High prevalence of viral genomes and multiple viral infections in the myocardium of adults with 'idiopathic' left ventricular dysfunction. Circulation 111, 887-893 (2005).
26. Kühl U, Pauschinger M, Seeberg B et al.: Viral persistence in the myocardium is associated with progressive cardiac dysfunction. Circulation 112, 1965-1970 (2005).
27. Enders G, Dotsch J, Bauer J et al.: Life-threatening parvovirus B19-associated myocarditis and cardiac transplantation as possible therapy: two case reports. Clin. Infect. Dis. 26, 355-358 (1998).
28. Heegaard ED, Eiskjaer H, Baandrup U, Hornsleth A: Parvovirus B19 infection associated with myocarditis following adult cardiac transplantation. Scand. J. Infect. Dis. 30, 607-610 (1998).
29. Bultmann BD, Klingel K, Sotlar K et al.: Fatal parvovirus B19-associated myocarditis clinically mimicking ischemic heart disease: an endothelial cell-mediated disease. Hum. Pathol. 34, 92-95 (2003).
30. Janner D, Bork J, Baum M, Chinnock R: Severe pneumonia after heart transplantation as a result of human parvovirus B19. J. Heart Lung Transplant. 13, 336-338 (1994).
31. Diaz F, Collazos J: Glomerulonephritis and Henoch-Schoenlein purpura associated with acute parvovirus B19 infection. Clin. Nephrol. 53, 237-238 (2000).
32. Nakazawa T, Tomosugi N, Sakamoto K et al.: Acute glomerulonephritis after human parvovirus B19 infection. Am. J. Kdney Dis. 35, E31 (2000).
33. Hillingso JG, Jensen IP, Tom-Petersen L: Parvovirus B19 and acute hepatitis in adults. Lancet 351, 955-956 (1998).
34. Yoto Y, Kudoh T, Haseyama K, Suzuki N, Chiba S: Human parvovirus B19 infection associated with acute hepatitis. Lancet 347, 868-869 (1996).
35. Karetnyi YV, Beck PR, Markin RS, Langnas AN, Naides SJ: Human parvovirus B19 infection in acute fulminant liver failure. Arch. Virol. 144, 1713-1724 (1999).
36. Langnas AN, Markin RS, Cattral MS, Naides SJ: Parvovirus B19 as a possible causative agent of fulminant liver failure and associated aplastic anemia. Hepatology 22, 1661-1665 (1995).
37. Barah F, Vallely PJ, Chiswick ML, Cleator GM, Kerr JR: Association of human parvovirus B19 infection with acute meningoencephalitis. Lancet 358, 729-730 (2001).
38. Barah F, Vallely PJ, Cleator GM, Kerr JR: Neurological manifestation of human parvovirus B19 infection. Rev. Med. Virol. 13, 185-199 (2003).
39. Lehmann HW, von Landenberg P, Modrow S: Parvovirus B19 infection and autoimmune disease. Autoimmunity Rev. 2, 218-223 (2003).
40. Erdman DD, Durigon EL, Wang QY, Anderson LJ: Genetic diversity of human parvovirus B19: sequence analysis of the VP1/VP2 gene from multiple isolates.J. Gen. Virol. 77(Pt 11), 2767-2774 (1996).
41. Zakrzewska K, Azzi A, De Biasi E et al.: Persistence of parvovirus B19 DNA in synovium of patients with haemophilic arthritis. J. Med. Virol. 65, 402-407 (2001).
42. Mori J, Beattie P, Melton DW, Cohen BJ, Clewley JP: Structure and mapping of the DNA of human parvovirus B19. J. Gen. Virol. 68(Pt 11), 2797-2806 (1987).
43. Gallinella G, Venturoli S, Gentilomi G, Musiani M, Zerbini M: Extent of sequence variability in a genomic region coding for capsid proteins of B19 parvovirus. Arch. Virol. 140, 1119-1125 (1995).
44. Hemauer A, von Poblotzki A, Gigler A et al.: Sequence variability among different parvovirus B19 isolates. J. Gen. Virol. 77(Pt 8), 1781-1785 (1996).
45. Dorsch S, Kaufmann B, Schaible U, Prohaska E, Wolf H, Modrow S: The VP1-unique region of parvovirus B19: amino acid variability and antigenic stability. J. Gen. Virol. 82, 191-199 (2001).
46. Hokynar K, Brunstein J, Söderlund-Venermo M et al.: Integrity and full coding sequence of B19 virus DNA persisting in human synovial tissue. J. Gen. Virol. 81, 1017-1025 (2000).
47. Doerig C, Hirt B, Antonietti JP, Beard P: Nonstructural protein of parvoviruses B19 and minute virus of mice controls transcription. J. Virol. 64, 387-396 (1990).
48. Nguyen QT, Sifer C, Schneider V, Bernaudin F, Auguste V, Garbarg-Chenon A: Detection of an erythrovirus sequence distinct from B19 in a child with acute anaemia. Lancet 352, 1524 (1998).
49. Nguyen QT, Sifer C, Schneider V et al.: Novel human Erythrovirus associated with transient aplastic anemia. J. Clin. Microbiol. 37, 2483-2487 (1999).
50. Hokynar K, Söderlund-Venermo M, Pesonen M et al.: A new parvovirus genotype persistent in human skin. Virology 302, 224-228 (2002).
51. Nguyen QT, Wong S, Heegaard ED, Brown KE: Identification and characterization of a second novel human Erythrovirus variant, A6. Virology 301, 374-380 (2002).
52. Servant A, Laperche S, Lallemand F et al.: Genetic diversity within human erythroviruses: identification of three genotypes. J. Virol. 76, 9124-9134 (2002).
53. Parsyan A, Szmaragd C, Allain JP, Candotti D: Identification and genetic diversity of two human parvovirus B19 genotype 3 subtypes. J. Gen. Virol. 88, 428-431 (2007).
54. Toan NL, Duechting A, Kremsner PG et al.: Phylogenetic analysis of human parvovirus B19, indicating two subgroups of genotype 1 in Vietnamese patients. J. Gen. Virol. 87, 2941-2949 (2006).
55. Ozawa K, Kurtzman G, Young N: Replication of the B19 parvovirus in human bone marrow cell cultures. Science 233, 883-886 (1986).
56. Srivastava A. Lu L: Replication of B19 parvovirus in highly enriched hematopoietic progenitor cells from normal human bone marrow. J. Virol. 62, 3059-3063 (1988).
57. Brown KE, Mori J, Cohen BJ, Field AM: In vitro propagation of parvovirus B19 in primary foetal liver culture. J. Gen. Virol. 72(Pt 3), 741-745 (1991).
58. Yaegashi N, Shiraishi H, Takeshita T, Nakamura M, Yajima A, Sugamura K: Propagation of human parvovirus B19 in primary culture of erythroid lineage cells derived from fetal liver. J. Virol. 63, 2422-2426 (1989).
59. Shimomura S, Komatsu N, Frickhofen N, Anderson S, Kajigaya S, Young NS: First continuous propagation of B19 parvovirus in a cell line. Blood 79, 18-24 (1992).
60. Miyagawa E, Yoshida T, Takahashi H et al.: Infection of the erythroid cell line, KU812Ep6 with human parvovirus B19 and its application to titration of B19 infectivity. J. Virol. Methods 83, 45-54 (1999).
61. Munakata Y, Kato I, Saito T, Kodera T, Ishii KK, Sasaki T: Human parvovirus B19 infection of monocytic cell line U937 and antibody-dependent enhancement. Virology 345, 251-257 (2006).
62. Brown KE, Anderson SM, Young NS: Erythrocyte P antigen: cellular receptor for B19 parvovirus. Science 262, 114-117 (1993).
63. Munakata Y, Saito-Ito T, Kumura-Ishii K et al.: Ku80 autoantigen as a cellular coreceptor for human parvovirus B19 infection. Blood 106, 3449-3456 (2005).
64. Weigel-Kelley KA, Yoder MC, Srivastava A: α5β1 integrin as a cellular coreceptor for human parvovirus B19: requirement of functional activation of betal integrin for viral entry. Blood 102, 3927-3933 (2003).
65. Liu JM, Green SW, Shimada T, Young NS: A block in full-length transcript maturation in cells noripermissive for B19 parvovirus. J. Virol. 66, 4686-4692 (1992).
66. Brunstein J, Söderlund-Venermo M, Hedman K: Identification of a novel RNA splicing pattern as a basis of restricted cell tropism of erythrovirus B19. Virology 274, 284-291 (2000).
67. Pallier C, Greco A, Le Junter J, Saib A, Vassias I, Morinet F: The 3' untranslated region of the B19 parvovirus capsid protein mRNAs inhibits its own mRNA translation in nonpermissive cells. J. Virol. 71, 9482-9489 (1997).
68. Yoto Y, Qui J, Pintel DJ: Identification and characterization of two internal cleavage and polyadenylation sites of parvovirus B19 RNA. J. Virol. 80, 1604-1609 (2006).
69. Blümel J, Eis-Hübinger AM, Stühler A, Bonsch C, Gessner M, Lower J: Characterization of Parvovirus B19 genotype 2 in KU812Ep6 cells. J. Virol. 79, 14197-14206 (2005).
70. Ekman A, Hokynar K, Kakkola L et al.: Biological and immunological relation of human parvovirus B19 genotypes 1-3. J. Virol. (2007) (Epub ahead of print).
71. Gareus R, Gigler A, Hemauer A et al.: Characterization of cis-acting and NS1 protein-responsive elements in the p6 promoter of parvovirus B19. J. Virol. 72, 609-616 (1998).
72. Heegaard ED, Petersen BL, Heilmann CJ, Hornsleth A: Prevalence of parvovirus B19 and parvovirus V9 DNA and antibodies in paired bone marrow and serum samples from healthy individuals. J. Clin. Microbiol. 40, 933-936 (2002).
73. Parsyan A, Kerr S, Owusu-Ofori S, Elliott G, Allain JP: Reactivity of genotype-specific recombinant proteins of human erythrovirus B19 with plasmas from areas where genotype 1 or 3 is endemic. J. Clin. Microbiol. 44, 1367-1375 (2006).
74. Tattersall P: The evolution of parvovirus taxonomy. In: Parvoriruses. Kerr JR (Ed.). Landon, Hodder Arnold, London, UK 5-14 (2006).
75. ICTVdB - The Universal Virus Database, version 4. Büchen-Osmond C (Ed.). Columbia University, NY, USA (2006).
76. Heegaard ED, Qvortrup K, Christensen J: Baculovirus expression of erythrovirus V9 capsids and screening by ELISA: serologic cross-reactivity with erythrovirus B19. J. Med. Virol. 66, 246-252 (2002).
77. LaMonte AC, Paul ME, Read JS et al.: Persistent parvovirus B19 infection without the development of chronic anemia in HIV-infected and -uninfected children: the Women and Infants Transmission Study. J. Infect. Dis. 189, 847-851 (2004).
78. Foto F, Saag KG, Scharosch LL, Howard EJ, Naides SJ: Parvovirus B19-specific DNA in bone marrow from B19 arthropathy patients: evidence for B19 virus persistence. J. Infect. Dis. 167, 744-748 (1993).
79. Sasaki T, Murai C, Muryoi T et al.: Persistent infection of human parvovirus B19 in a normal subject. Lancet 346, 851 (1995).
80. Cassinoti P, Burtonboy G, Fopp M, Siegl G: Evidence for persistence of human parvovirus B19 DNA in bone marrow. J. Med. Virol. 53, 229-232 (1997).
81. Heegaard ED, Brown KE: Human parvovirus B19. Clin. Microbiol. Rev. 15, 485-505 (2002).
82. Lundqvist A, Isa A, Tolfvenstam T, Kvist G, Broliden K: High frequency of parvovirus B19 DNA in bone marrow samples from rheumatic patients. J. Clin. Virol. 33, 71-74 (2005).
83. Lundqvist A, Tolfvenstam T, Brytring M, Stolt CM, Hedman K, Broliden K: Prevalence of parvovirus B19 DNA in bone marrow of patients with haematological disorders. Scand. J. Infect. Dis. 31, 119-122 (1999).
84. Musiani M, Zerbini M, Gentilomi G, Plazzi M, Gallinella G, Venturoli S: Parvovirus B19 clearance from peripheral blood after acute infection. J. Infect. Dis. 172, 1360-1363 (1995).
85. Lindblom A, Isa A, Norbeck O et al.: Slow clearance of human parvovirus B19 viremia following acute infection. Clin. Infect. Dis. 41, 1201-1203 (2005).
86. Candotti D, Etiz N, Parsyan A, Allain JP: Identification and characterization of persistent human erythrovirus infection in blood donor samples. J. Virol. 78, 12169-12178 (2004).
87. Lefrere JJ, Servant-Delmas A, Candotti D et al.: Persistent B19 infection in immunocompetent individuals: implications for tranfusion safety. Blood 106, 2890-2895 (2005).
88. Heegaard ED, Panum Jensen I, Christensen J: Novel PCR assay for differential detection and screening of erythrovirus B19 and erythrovirus V9. J. Med. Virol. 65, 362-367 (2001).
89. Hokynar K, Norja P, Laitinen H et al.: Detection and differentiation of human parvovirus variants by commercial quantitative real-time PCR tests. J. Clin. Microbiol. 42, 2013-2019 (2004).
90. Norja P, Hokynar K, Aaltonen LM et al.: Bioportfolio: lifelong persistence of variant and prototypic Erythrovirus DNA genomes in human tissue. Proc. Natl Acad. Sci. USA 103, 7450-7453 (2006).
91. Braham S, Gandhi J, Beard S, Cohen B: Evaluation of the Roche LightCycler parvovirus B19 quantification kit for the diagnosis of parvovirus B19 infections. J. Clin. Virol. 31, 5-10 (2004).
92. Cohen BJ, Gandhi J, Clewley JP: Genetic variants of parvovirus B19 identified in the United Kingdom: implications for diagnostic testing. J. Clin. Virol. 36, 152-155 (2006).
93. Liefeldt L, Plentz A, Klempa B et al.: Recurrent high level parvovirus B19/genotype 2 viremia in a renal transplant recipient analyzed by real-time PCR for simultaneous detection of genotypes 1 to 3. J. Med. Virol. 75, 161-169 (2005).
94. Schneider B, Becker M, Brackmann HH, Eis-Hübinger AM: Contamination of coagulation factor concentrates with human parvovirus B19 genotype 1 and 2. Thromb. Haemost. 92, 838-845 (2004).
95. Candotti D, Danso K, Parsyan A, Dompreh A, Allain JP: Maternal-fetal transmission of human parvovirus B19 genotype 3. J. Infect. Dis. 194, 608-611 (2006).
96. Sanabani S, Neto WK, Pereira J, Sabino EC: Sequence variability of human erythroviruses present in bone marrow of Brazilian patients with various parvovirus B19-related hematological symptoms. J. Clin. Microbiol. 44, 604-606 (2006).
97. Toan NL, Song le H, Kremsner PG et al.: Co-infection of human parvovirus B19 in Vietnamese patients with hepatitis B virus infection. J. Hepatol. 45, 361-369 (2006).
98. Franssila R, Hedman K: Infection and musculoskeletal conditions: Viral causes of arthritis. Best Pract. Res. Clin. Rheumatol. 20, 1139-1157 (2006).
99. Saal JG, Steidle M, Einsele H, Müller CA, Fritz P, Zacher J: Persistence of B19 parvovirus in synovial membranes of patients with rheumatoid arthritis. Rheumatol. Int. 12, 147-151 (1992).
100. Cassinotti P, Siegl G, Michel BA, Brühlmann P: Presence and significance of human parvovirus B19 DNA in synovial membranes and bone marrow from patients with arthritis of unknown origin. J. Med. Virol. 56, 199-204 (1998).
101. Dijkmans BA, van Elsacker-Niele AM, Salimans MM, van Albada-Kuipers GA, de Vries E, Weiland HT: Human parvovirus B19 DNA in synovial fluid. Arthritis Rheum. 31, 279-281 (1988).
102. Nikkari S, Roivainen A, Hannonen P et al.: Persistence of parvovirus B19 in synovial fluid and bone marrow. Ann. Rheum. Dis. 54, 597-600 (1995).
103. Kerr JR, Cartron JP, Curran MD, Moore JE, Elliott JR, Mollan RA: A study of the role of parvovirus B19 in rheumatoid arthritis. Br. J. Rheumatol. 34, 809-813 (1995).
104. Söderlund-Venermo M, Hokynar K, Nieminen J, Rautakorpi H, Hedman K: Persistence of human parvovisus B19 in human tissues. Pathol. Biol. (Paris) 50, 307-316 (2002).
105. Söderlund M, von Essen R, Haapasaari J, Kiistala U, Kiviluoto O, Hedman K: Persistence of parvovirus B19 DNA in synovial membranes of young patients with and without chronic arthropathy. Lancet 349, 1063-1065 (1997).
106. Chevrel G, Calvet A, Belin V, Miossec P: Dermatomyositis associated with the presence of parvovirus B19 DNA in muscle. Rheumatology (Oxford) 39, 1037-1039 (2000).
107. Hobbs JA: Detection of adeno-associated virus 2 and parvovirus B19 in the human dorsolateral prefrontal cortex. J. Neurovirol. 12, 190-199 (2006).
108. Gray A, Guillou L, Zufferey J et al.: Persistence of parvovirus B19 DNA in testis of patients with testicular germ cell tumours. J. Gen. Virol. 79(Pt 3), 573-579 (1998).
109. Diss TC, Pan LX, Du MQ, Peng HZ, Kerr JR: Parvovirus B19 is associated with benign testes as well as testicular germ cell tumours. Mol. Pathol. 52, 349-352 (1999).
110. Vuorinen T, Lammintausta K, Kotilainen P, Nikkari S: Presence of parvovirus B19 DNA in chronic urticaric and healthy human skin. J. Clin. Virol. 25, 217-221 (2002).
111. Baskan EB, Yilmaz E, Saricaoglu H et al.: Detection of parvovirus B19 DNA in the lesional skin of patients with Behcet's disease. Clin. Exp. Dermatol. 32, 186-190 (2007).
112. Eis-Hübinger AM, Reber U, Abdul-Nour T, Glatzel U, Lauschke H, Pütz U: Evidence for persistence of parvovirus B19 DNA in livers of adults. J. Med. Virol. 65, 395-401 (2001).
113. Manning A, Willey SJ, Bell JE, Simmonds P: Comparison of tissue distribution, persistence, and molecular epidemiology of parvovirus B19 and novel human Parvoviruses PARV4 and Human Bocavirus. J. Infect. Dis. 195, 1345-1352 (2007).
114. Lotze U, Egerer R, Tresselt C et al.: Frequent detection of parvovirus B19 genome in the myocardium of adult patients with idiopathic dilated cardiomyopathy. Med. Microbiol. Immunol. 193, 75-82 (2004).
115. De Stefano R, Manganelli S, Frati E et al.: No association between human parvovirus B19 infection and Sjogren's syndrome. Ann. Rheum. Dis. 62, 86-87 (2003).
116. Gao G, Vandenberghe LH, Alvira MR et al.: Clades of Adeno-associated viruses are widely disseminated in human tissues. J. Virol. 78, 6381-6388 (2004).
117. Wong S, Young NS, Brown KE: Prevalence of parvovirus B19 in liver tissue: no association with fulminant hepatitis or hepatitis-associated aplastic anemia. J. Infect. Dis. 187, 1581-1586 (2003).
118. Cooling LL, Koerner TA, Naides SJ: Multiple glycosphingolipids determine the tissue tropism of parvovirus B19. J. Infect. Dis. 172, 1198-1205 (1995).
119. Weigel-Kelley KA, Yoder MC, Srivastava A: Recombinant human parvovirus B19 vectors: erythrocyte P antigen is necessary but not sufficient for successful transduction of human hematopoietic cells. J. Virol. 75, 4110-4116 (2001).
120. Ponnazhagan S, Weigel KA, Raikwar SP, Mukherjee P, Yoder MC, Srivastava A: Recombinant human parvovirus B19 vectors: erythroid cell-specific delivery and expression of transduced genes. J. Virol. 72, 5224-5230 (1998).
121. Weigel-Kelley KA, Yoder MC, Chen L, Srivastava A: Role of integrin cross-regulation in parvovirus B19 targeting. Hum. Gene Ther. 17, 909-920 (2006).
122. Ray NB, Nieva DR, Seftor EA, Khalkhali-Ellis Z, Naides SJ: Induction of an invasive phenotype by human parvovirus B19 in normal human synovial fibroblasts. Arthritis Rheum. 44, 1582-1586 (2001).
123. Lu J, Zhi N, Wong S, Brown KE: Activation of synoviocytes by the secreted phospholipase A2 motif in the VP1-unique region of parvovirus B19 minor capsid protein. J. Infect. Dis. 193, 582-590 (2006).
124. Poole BD, Karetnyi YV, Naides SJ: Parvovirus B19-induced apoptosis of hepatocytes. J. Virol. 78, 7775-7783 (2004).
125. Poole BD, Zhou J, Grote A, Schiffenbauer A, Naides SJ: Apoptosis of liver-derived cells induced by parvovirus B19 nonstructural protein. J. Virol. 80, 4114-4121 (2006).
126. Ferri C, Giuggioli D, Sebastiani M et al.: Parvovirus B19 infection of cultured skin fibroblasts from systemic sclerosis patients: comment on the article by Ray et al. Arthritis Rheum. 46, 2262-2263 (2002).
127. Magro CM, Crowson AN, Dawood M, Nuovo GJ: Parvoviral infection of endothelial cells and its possible role in vasculitis and autoimmune diseases. J. Rheumatol. 29, 1227-1235 (2002).
128. Magro CM, Nuovo G, Ferri C, Crowson AN, Giuggioli D, Sebastiani M: Parvoviral infection of endothelial cells and stromal fibroblasts: a possible pathogenetic role in scleroderma. J. Cutan. Pathol. 31, 43-50 (2004).
129. Zakrzewska K, Cortivo R, Tonello C et al.: Human parvovirus B19 experimental infection in human fibroblasts and endothelial cells cultures. Virus Res. 114, 1-5 (2005).
130. Gallinella G, Manaresi E, Zuffi E et al.: Different patterns of restriction to B19 parvovirus replication in human blast cell lines. Virology 278, 361-367 (2000).
131. Kotin RM, Siniscalco M, Samulski RJ et al.: Site-specific integration by adeno-associated virus. Proc. Natl Acad. Sci. USA 87, 2211-2215 (1990).
132. Kotin RM, Menninger JC, Ward DC, Berns KI: Mapping and direct visualization of a region-specific viral DNA integration site on chromosome 19q13-qter. Genomics 10, 831-834 (1991).
133. Kotin RM, Linden RM, Berns KI: Characterization of a preferred site on human chromosome 19q for integration of adeno-associated virus DNA by non-homologous recombination. EMBO J. 11, 5071-5078 (1992).
134. Corsini J, Tal J, Winocour E: Directed integration of minute virus of mice DNA into episomes. J. Virol. 71, 9008-9015 (1997).
135. Muetherig A, Christopeit M, Müller LP et al.: Human parvovirus B19 infection with GvHD-like erythema in two allogeneic stem cell transplant recipients. Bone Marrow Transplant. 39, 315-316 (2007).
136. Söderlund M, Ruutu P, Ruutu T, Asikainen K. Franssila R, Hedman K: Primary and secondary infections by human parvovirus B19 following bone marrow transplantation: characterization by PCR and B-cell molecular immunology. Scand. J. Infect. Dis. 29, 129-135 (1997).
137. Kerr JR, Boschetti N: Short regions of sequence identity between the genomes of human and rodent parvoviruses and their respective hosts occur within host genes for the cytoskeleton, cell adhesion and Wnt signalling. J. Gen. Virol. 87, 3567-3575 (2006).